公开(公告)号：US20250057886A1

公开(公告)日：2025-02-20

申请号：US18842871

申请日：2023-03-02

Applicant: Lineage Cell Therapeutics, Inc.

Inventor： Olga MIZRAHI ,  Rami SKALITER ,  Francois BINETTE ,  Dana HAYOUN NEEMAN ,  Ofer WISER ,  Lilach ALON

IPC: A61K35/36 ,  A61K9/00 ,  C12N5/0793

Abstract: Provided herein are methods for inducing cellular differentiation of undifferentiated stem cells into cells capable of functioning as sensory cells of the ear, and to pharmaceutical compositions for treating auditory conditions in a subject.

公开(公告)号：US20240299625A1

公开(公告)日：2024-09-12

申请号：US18567163

申请日：2023-12-05

Applicant: Lineage Cell Therapeutics, Inc.

Inventor： Rami Skaliter ,  Gary Hogge ,  Jordi Mones ,  Avi Ben Shabat ,  Lilach Alon ,  Ravid Tikotzki ,  Dana Hayoun Neeman ,  Ofer Wiser

IPC: A61L27/38 ,  A61B3/00 ,  A61B3/10 ,  A61B3/12 ,  A61B5/00 ,  A61F2/14 ,  G06T7/00 ,  G06T7/62 ,  G16H50/20

CPC classification number: A61L27/3869 ,  A61B3/0025 ,  A61B3/102 ,  A61B3/1225 ,  A61B5/4842 ,  A61B5/4848 ,  A61F2/14 ,  A61L27/3813 ,  G06T7/0016 ,  G06T7/62 ,  G16H50/20 ,  A61L2430/16 ,  G06T2207/10101 ,  G06T2207/30041

Abstract: Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.

公开(公告)号：US20230210978A1

公开(公告)日：2023-07-06

申请号：US17995008

申请日：2021-04-02

Applicant: Francois BINETTE ,  Brian M. CULLEY ,  Rami SKALITER ,  LINEAGE CELL THERAPEUTICS, INC.

Inventor： Francois BINETTE ,  Brian M. CULLEY ,  Rami SKALITER

IPC: A61K39/215 ,  C12N5/0784 ,  A61P31/14

CPC classification number: A61K39/215 ,  C12N5/0639 ,  A61P31/14 ,  C12N2770/20034 ,  A61K2039/5154

Abstract: Provided herein are methods and compositions for engineering antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages, and B-Cells, that are modified to express viral antigens. With this approach, large cell banks can be created that can be rapidly modified and deployed to fight various types of infectious diseases such as those associated with coronaviruses and other viral infections.

公开(公告)号：US20210155895A1

公开(公告)日：2021-05-27

申请号：US16090871

申请日：2017-04-04

Applicant: LINEAGE CELL THERAPEUTICS, INC.

Inventor： Igor Olegovich Nasonkin ,  Ratnesh Singh ,  Michael D. West ,  Hal Sterberg ,  David LAROCCA

IPC: C12N5/00 ,  C12N5/079

Abstract: Pluripotent stem cell-derived 3D retinal organoid compositions and methods of making using the same are disclosed.

公开(公告)号：US20040204386A1

公开(公告)日：2004-10-14

申请号：US10671070

申请日：2003-09-24

Applicant: Cell Therapeutics, Inc.

Inventor： Rama Bhatt ,  Baoqing Gong ,  Feng Hong ,  Scott A. Jenkins ,  J. Peter Klein ,  Cory T. Kohm ,  John Tulinsky

IPC: A61K031/69 ,  A61K031/505 ,  A61K031/513

CPC classification number: C07D239/48 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity and/or proliferation of cells such as tumor-cells.

Abstract translation: 本发明涉及嘧啶及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

公开(公告)号：US20040043465A1

公开(公告)日：2004-03-04

申请号：US10667494

申请日：2003-09-23

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Daniel Adourel ,  David Hollenback

IPC: C12N009/10 ,  C07H021/04

CPC classification number: C12N9/1029

Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

公开(公告)号：US20030216289A1

公开(公告)日：2003-11-20

申请号：US10407217

申请日：2003-04-07

Applicant: Cell Therapeutics, Inc.

Inventor： Rama Bhatt ,  Peter de Vries ,  J. Peter Klein ,  John Tulinsky ,  Robert A. Lewis ,  Jack W. Singer

IPC: A61K038/16 ,  C07K014/00

CPC classification number: C07K5/06026 ,  A61K47/54 ,  A61K47/645 ,  C07K1/1077 ,  C07K5/0806

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

公开(公告)号：US20030211973A1

公开(公告)日：2003-11-13

申请号：US10407218

申请日：2003-04-07

Applicant: Cell Therapeutics, Inc.

Inventor： Rama Bhatt ,  Peter de Vries ,  J. Peter Klein ,  John Tulinsky ,  Robert A. Lewis ,  Jack W. Singer

IPC: A61K038/00

CPC classification number: C07K5/06026 ,  A61K47/54 ,  A61K47/645 ,  C07K1/1077 ,  C07K5/0806

Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.

公开(公告)号：US20030073615A1

公开(公告)日：2003-04-17

申请号：US10146809

申请日：2002-05-17

Applicant: Cell Therapeutics, Inc.

Inventor： Chun Li ,  Sidney Wallace ,  Dong-Fang Yu ,  David J. Yang

IPC: A61K038/00

CPC classification number: A61K41/0038 ,  A61K31/337 ,  A61K31/4375 ,  A61K38/13 ,  A61K47/547 ,  A61K47/59 ,  A61K47/60 ,  A61K47/645 ,  A61K51/0497 ,  A61K51/065 ,  A61K2121/00 ,  A61K2123/00 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/606 ,  C08G73/1092

Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

公开(公告)号：US20020150945A1

公开(公告)日：2002-10-17

申请号：US10172715

申请日：2002-06-13

Applicant: Cell Therapeutics, Inc.

Inventor： Robert Finney ,  David Leung ,  Alan Lofquist

IPC: C12Q001/68 ,  C12M001/34

CPC classification number: C12N15/85 ,  C12N15/10 ,  C12N15/1034 ,  C12N15/902

Abstract: A method for high-throughput genomics analysis, to identify the therapeutic or diagnostic utility of genes, entails the use of a construct to disrupt a gene or alleles of a gene in cells of interest. Arrays of such cells can be used to monitor such disrupted cells phenotypically in the context, for example, of testing drug candidates. Polynucleotides that comprise part of the disrupted genes can be recovered from such nullknockoutnull cells, by virtue of an origin of replication or a host cell selection marker sequence that is part of the construct. The recovered polynucleotides can be used to identify the disrupted genes or to make homologous recombination vectors, which in turn can be employed to make multi-allele knockout cells. Double-stranded RNA molecules designed to target the recovered polynucleotide are used to downregulate the polynucleotide in vitro and in vivo, following determination of a therapeutically effective dosage of the RNAi molecule.

Abstract translation: 用于识别基因的治疗或诊断效用的高通量基因组学分析的方法需要使用构建体来破坏目的细胞中基因的基因或等位基因。 这种细胞的阵列可以用于在上下文中表型地监测这样的破坏细胞，例如测试候选药物。 可以通过复制起点或作为构建体一部分的宿主细胞选择标记序列从这种“敲除”细胞中回收构成部分破坏基因的多核苷酸。 回收的多核苷酸可用于鉴定破坏的基因或使同源重组载体，其又可用于制备多等位基因敲除细胞。 在测定治疗有效剂量的RNAi分子后，设计用于靶向回收多核苷酸的双链RNA分子用于体外和体内下调多核苷酸。